FDA Commissioner Predicts New Treatments for Cancer and Neurodegenerative Diseases
Dr. Marty McCulley, the Commissioner of the FDA, has expressed optimism about “powerful” new treatments for various cancers and neurodegenerative diseases—like Alzheimer’s, Parkinson’s, and ALS—possibly becoming available in the next few years.
McCulley highlighted the FDA’s commitment to making the drug approval process more efficient, stating that his team is diligently working on promising treatments to expedite their delivery to patients. “I think during our time in office, in this administration, we’re going to see significant advancements in treating some cancers and neurodegenerative diseases,” he shared with Miranda Devine.
When pressed about specific conditions, he mentioned, “Alzheimer’s disease, Parkinson’s disease, and ALS. We are actively looking for impactful treatments.”
The process for reviewing new drugs at the FDA is often seen as slow and complicated, with costs for developing a new drug ranging from $2 billion to $3 billion, as noted in a study. “It currently takes 10 to 12 years for a drug to reach the market, which does seem somewhat unreasonable. We’re questioning that standard,” McCulley stated. “We have a new program in place aimed at making timely decisions.”
While emphasizing the importance of faster approvals, McCulley reiterated that safety is always the top priority. “We need to collaborate with these pharmaceutical companies to bring more solutions to the American public, while ensuring that our review process remains independent and scientifically sound,” he added.
To expedite treatment availability, McCulley is focused on cutting through bureaucratic red tape that can delay approvals. Part of this new approach includes engaging directly with scientists developing promising treatments and assisting them through the intricate approval landscape.
As an illustrative case, he mentioned a study from the New England Medical Journal that reported certain children experiencing improvements in hearing loss through innovative gene therapy. “We contacted the company immediately, reviewed the research, and granted them a priority review voucher within weeks,” he noted.
“We can’t adopt the passive, bureaucratic mindset that often dominates; we can’t be the stingy librarians who reject applications for minor formatting issues,” McCulley remarked.
Recalling the significant speed-up in vaccine development during the Trump administration’s Operation Warp Speed, which made a COVID-19 vaccine available in under a year, he acknowledged the potential for efficiency in drug approvals.
McCulley has also exhibited skepticism regarding previous COVID-19 vaccination policies and favored the Trump administration’s decision to halt vaccine recommendations for healthy children and pregnant individuals. However, he remains motivated to eliminate unnecessary bureaucratic obstacles that hinder progression toward effective treatments.
“I want to understand how to treat PTSD, especially for veterans who continue to battle with the aftermath of war. I also believe everyone should receive a flu shot to minimize seasonal outbreaks,” he emphasized. “Our focus is on discovering powerful new treatments.”
Additionally, McCulley has worked to remove some controversial animal testing requirements that his predecessors had adhered to. He reflected on the backlash against painful experiments conducted on animals, specifically citing Dr. Anthony Fauci’s past criticisms regarding such practices.
“We’ve found that utilizing computer modeling can often be more effective than traditional animal testing,” he explained. “Some drugs have previously been held up for animal testing despite being safe for humans. We could be missing valuable treatments by sticking with outdated methods. We’re shifting toward using organ cell lines for drug testing in the lab.”
